BIOMARK DIAGNOSTICS REVIEWS 2019 AND OUTLINES PLANS FOR 2020
Vancouver, British Columbia – (December 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to provide 2019 round up and our outlook for 2020. Below are key highlights. 2019 Round Up 2019 has been a transformative year for BioMark and we anticipate that 2020 would be another […]
BIOMARK CLOSES THE OVER-SUBSCRIBED PRIVATE PLACEMENT OFFERING
Vancouver, British Columbia – (December 16th, 2019) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of November 21st, 2019, it has closed the non-brokered private placement for gross proceeds of $669,347.00 wherein BioMark issued 2,231,157 units at a price […]
Canadian Trade Commissioner Service Features BioMark Diagnostics Next Generation Cancer Diagnostics
Vancouver, British Columbia – (December 11th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) with the help of the Canadian Trade Commissioner Service (TCS) is developing dynamic global connections and undertaking research collaborations in an effort to bring its “next-generation” cancer diagnostics technology to market. BioMark is excited and proud to […]
BIOMARK ANNOUNCES PRIVATE PLACEMENT
Vancouver, British Columbia – (November 21st, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 1,666,667 Units at a price of $0.30 to raise gross proceeds of up to $500,000. Each Unit is composed […]
BIOMARK Announces Private Placement
Press_Release_BIOMARK_ANNOUNCES_PRIVATE_PLACMENT_May_9th_2017 (PDF)
BioMark Signs Letter of Intent for Licensing Relationship for Clinical Validation and Development
Vancouver, British Columbia – (November 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has signed a Letter of Intent (LOI) with a Chinese company named GuangDong Longhu (Longhu) related to an anticipated licensing relationship. BioMark has been in discussions with Longhu and its management […]
NEW SCIENTIFIC PUBLICATION FURTHER SUPPORTS BIOMARK’S ASSAY
Vancouver, British Columbia – (August 27th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Predictive value and clinical significance of increased SSAT-1 activity in healthy adults” has been published in the peer-reviewed journal Future Science OA. Rashid Ahmed, President and CEO, says, “This […]
BIOMARK’S LIQUID BIOPSY SCIENTIFIC PAPER TO BE FEATURED AS COVER ON CANCERS UPCOMING ISSUE
Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of Cancers. Rashid Ahmed, President and CEO, says, “This latest paper […]
BIOMARK’S LIQUID BIOPSY SCIENTIFIC PAPER TO BE FEATURED AS COVER ON CANCERS UPCOMING ISSUE
Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of Cancers. Rashid Ahmed, President and CEO, says, “This latest […]
NEW ADVANCES IN LIQUID BIOPSY TO INCREASE BIOMARK’S ASSAY PERFORMANCE
Vancouver, British Columbia – (August 13th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” has been published in the peer-reviewed journal Cancers. Rashid Ahmed, President and CEO, says, […]
